• Studies have shown that Semaglutide injections can be used together with diet and exercise to help control your blood sugar and help lose weight and keep the weight off.
• Nurses can now support patients with regular injections pursuant to a physician’s order and help improve patient outcomes.
• Hydreight provides an integrated, comprehensive mobile platform that connects healthcare professionals and their patients with pharmacies in the United States.
  

VANCOUVER, British Columbia and LAS VEGAS, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (“Hydreight” or the “Company”) (TSXV:NURS)(OTCQB:HYDTF)(FSE:S06) a mobile clinical network and medical platform which enables flexible, at-home medical services across 50 states in the United States, is excited to announce that healthcare providers and their patients now have access to Semaglutide through the Hydreight platform.

Semaglutide injections are commonly used to treat type 2 diabetes. It can also be used together with diet and exercise to help control blood sugar and has become popular to help with weight management. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist and is only available with a doctor’s prescription and needs to be injected on a regular basis. 

According to Goldman Sachs, it is projected that by 2030, the global market for anti-obesity medications (AOMs) could grow by more than 16 times to $100 billion. Based on current trends, over half of the global population will be overweight or obese by 2035, compared to 38% in 2020, according to a World Obesity Atlas 2023 forecast.¹

Shane Madden, CEO of Hydreight commented, “This is a significant inflection point for Hydreight and a pivotal point for our business. We have seen huge demand in the United States for medications like Semaglutide to help with weight management. Our revolutionary technology platform allows doctors and nurses to connect with patients and pharmacy networks to provide continuous care and improve patient outcomes. Adding access to Semaglutide through our platform is the first step in our shift from preventative medicine to essential healthcare, and we are only just getting started.”

Hydreight is revolutionizing mobile medicine by building the largest mobile clinical network in the United States which operates in over 650 cities nationally. Currently, Hydreight is utilizing its proprietary platform and mobile network to provide end to end care and has built the only platform that can now host the provision of fully integrated approach to patient care which includes, lab tests, doctors’ prescriptions, drug delivery, drug administering, patient monitoring and regular follow ups across the United States. 

Hydreight has a robust product offering and continues to add products to its legacy IV drip therapy solution. Over the last few months, Hydreight has added aesthetics and filler, as well as NAD+ to its platform. Next year, Hydreight's platform plans to expand to accommodate lab testing and 12 blood tests that can be taken at home or office with the support of a nurse. All these products allow healthcare providers using the Hydreight platform to provide a higher level of medicine and provide a pathway to shift into medical essentials.

^{1. https://www.goldmansachs.com/intelligence/pages/anti-obesity-drug-market.html}

About Hydreight Technologies Inc.

Hydreight Technologies Inc. is building the largest mobile clinic network in the United States. Its proprietary, fully integrated platform hosts a network of nearly 3,000 nurses, over 100 doctors and a pharmacy network across 50 states. The platform includes a built-in, easy-to-use suite of fully integrated tools for accounting, documentation, sales, inventory, booking, and managing patient data, which enables licensed healthcare professionals to provide services directly to patients at home, office or hotel. Hydreight empowers nurses, med spa technicians, and other licensed healthcare professionals to deliver services independently, on their own terms, or to add mobile services to existing location-based operations. The Hydreight platform hosts a 503B pharmacy network servicing all 50 states and is closely affiliated with a U.S. certified e-script and telemedicine provider network that provides services in over 650 cities and growing.

On behalf of the Board of Directors

Shane Madden
Director and Chief Executive Officer
Hydreight Technologies Inc.

Contact
Email: ir@hydreight.com; Telephone: (480) 790 6886

Cautionary Note Regarding Forward-Looking Information

This press release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect”, “Approximately” or similar expressions and includes information regarding the launch date of MedicalMedIV.com, and the anticipated effect on bookings and customer retention rates.

Investors are cautioned that forward-looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or predictions concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the ability to obtain requisite regulatory and other approvals with respect to the business operated by the Company and/or the potential impact of the listing of the Company’s shares on the TSXV on relationships, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation; and the diversion of management time as a result of being a publicly listed entity. This forward-looking information may be affected by risks and uncertainties in the business of the Company and market conditions.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

Neither TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

This press release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements.